| Previous Close | 0.1800 |
| Open | 0.1900 |
| Bid | 0.1800 x N/A |
| Ask | 0.1900 x N/A |
| Day's Range | 0.1850 - 0.1900 |
| 52 Week Range | 0.1800 - 0.3950 |
| Volume | 55,000 |
| Avg. Volume | 131,360 |
| Market Cap | 12.868M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
Rakovina Therapeutics Inc. Receives European and Canadian Patents on kt-2000 series PARP-inhibitors
Rakovina Therapeutics Inc. (the "Company") (TSXV: RKV) today announced that the Company has been granted patents entitled "Tricyclic Inhibitors of Poly(ADP-Ribose) Polymerase" by the European and Canadian Patent Offices.
- CNW Group
Rakovina Therapeutics Inc. Appoints Biotechnology Industry Veteran Julie M. Cherrington, PhD to Board of Directors
Rakovina Therapeutics Inc. (the "Company") (TSXV: RKV) is pleased to announce the appointment of Julie M. Cherrington, PhD to the Company's Board of Directors.
- Newsfile
InvestmentPitch Media Video Discusses Newly Listed Rakovina Therapeutics, a Developer of New Cancer Treatments Targeting Critical DNA Damage Response Mutations - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - April 5, 2021) - Rakovina Therapeutics Inc. is one of the latest new listings on the TSX Venture Exchange, trading under the symbol "RKV", following its qualifying transaction with Capital Pool Company Vincero Capital. The company's focus is the development of new cancer treatments and is researching and developing new precision medicines targeting critical DNA damage response mutations that are the hallmarks of many cancers.For more information, please view ...
